PD) patients. DBS in brain regions, particularly on the PPN, has been used for a number of years to improve the motor symptoms of PD. The improvement of motor symptoms following stimulation at the natural frequency of PPN cells suggests that the RAS plays a pivotal role in posture and locomotion. This system is intrinsically linked with muscle tone during sleep stages, especially muscle atonia during REM sleep. Accumulating evidence suggests that the RAS, especially the PPN that controls waking and REM sleep, is overactive in PD, possibly resulting in the high prevalence of sleep complaints, particularly insomnia (80%), in PD patients. With this in mind, electrical stimulation of the PPN has been undertaken, resulting in an improvement in non-motor symptoms of PD, such as sleep disturbances, by improving the tonic function of the RAS. One study reported that PPN DBS improved not only nighttime sleep, but also daytime sleepiness. The authors conclude that if PPN DBS can normalize wake/sleep characteristics, the technique should be further investigated regarding its positive outcomes on wake/sleep dysregulation in PD, and possibly, many other neurological disorders.
reciprocal interactions between the PPN and the ventral tegmental area (VTA) in the context of psychostimulant abuse. The VTA is a key neural substrate involved in the modulation of psychostimulant abuse, and its output is essential for the rewarding effects of addictive drugs. The VTA receives cholinergic RAS input from the PPN, which modulates states of waking and REM sleep, in a loop that includes the dopaminergic and GABAergic efferents from the medial prefrontal cortex (mPFC). Although not entirely understood, the anatomical connections between the PPN and the VTA suggest a link between PPN function, locomotor stimulation and reinforcement effects of psychostimulant drugs. For instance, PPN-lesioned animals presented reduced motivational effects of psychostimulants, indicated by decreased amphetamine self-administration. Taken together, the reviewed data highlights the importance of further experimentation, either by using brain lesions or pharmacological interventions, to determine the exact role of the PPN in psychostimulant abuse.
Both approaches can be helpful to increase understanding of the evolution of sleep disturbances, as well as to set specific goals in the treatment of neurological disorders.
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